30 July 2013
PLANT HEALTH CARE PLC
Plant Health Care announces plans for Harpin seed treatment
Plant Health Care (AIM: PHC), a leading provider of naturally derived products to the agriculture industry, announces that it has regained licensed rights to harpin αβ as a seed treatment. Plant Health Care and Monsanto have mutually agreed to discontinue the 2008 harpin αβ agreement which granted Monsanto certain exclusive rights to develop and sell harpin αβ as a seed treatment. Since the first usage in 2010, over 10,000,000 acres of harpin-treated soybeans have been planted. Under the terms of this mutual agreement, all licensed rights have reverted back to PHC and PHC has purchased Monsanto's remaining harpin inventory.
The agreement enables PHC to develop and sell harpin seed treatment into all crop markets, including corn, soybean, cotton, and canola, on a global basis.
Paul Schmidt, CEO at Plant Health Care, stated that "This agreement keeps the door open with Monsanto for their review of new technologies being developed within PHC, while enabling us to get closer to the market ourselves and to partner with others to fully exploit the potential of harpin as a seed treatment."
- ENDS-
About Plant Health Care, plc: Plant Health Care, plc ("PHC") is a leading provider of naturally derived products for plants and soil. The Company's ordinary shares have been quoted on the Alternative Investment Market ("AIM") of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") in February 2010 (ticker symbol/ mnemonic: PHC).
PHC's products are aimed at agriculture industries and are environmentally beneficial. Through the commercialisation of these products, PHC is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management. Further information is available at: www.planthealthcare.com.
For further information please contact:
Plant Health Care plc |
|
Paul Schmidt, Chief Executive Officer |
Tel: +1-412-826-5488 |
Stephen Weaver, Finance Director |
Tel: +1-412-826-5488 |
|
|
Nomura Code Securities |
Tel: +44 (0) 20 7776 1200 |
Clare Terlouw / Chris Golden |
|
|
|
Powerscourt |
Tel: +44 (0) 20 7250 1446 |
Paul Durman / Nick Dibden / Sophie Moate |
|